Y-mAbs Therapeutics, Inc represents values of dedication, innovation, and patient-centered care. As a biopharmaceutical company, Y-mAbs is committed to developing and commercializing novel antibody-based therapies to address unmet medical needs in pediatric and adolescent patients. Their corporate philosophy emphasizes cutting-edge research, scientific expertise, and a relentless pursuit of improving patients' lives. With a focus on oncology and neuroblastoma, Y-mAbs strives to bring transformative treatments to those in need. Through their dedication to scientific advancements and patient-centric approach, Y-mAbs Therapeutics, Inc aims to make a positive impact on the lives of individuals affected by these diseases.

Y-mAbs Therapeutics, Inc primarily operates in the United States.

Y-mAbs Therapeutics, Inc has achieved several significant milestones. The company obtained accelerated approval from the U.S. FDA for naxitamab in March 2020, for the treatment of high-risk neuroblastoma in pediatric patients aged 1 year and above. Furthermore, Y-mAbs Therapeutics, Inc successfully completed a rolling submission of a Biologics License Application (BLA) in October 2020, seeking full approval for naxitamab, a monoclonal antibody. These achievements highlight the company's commitment to developing innovative therapies for pediatric patients with high-risk neuroblastoma and their dedication to obtaining necessary regulatory approvals. Y-mAbs Therapeutics, Inc's milestones demonstrate their progress in advancing effective medical solutions in the field of oncology.

Y-mAbs Therapeutics, Inc is a biopharmaceutical company specializing in the development and commercialization of innovative antibody-based therapies. Established in 2015, Y-mAbs focuses on developing treatments for pediatric and adult oncology and neuroblastoma. The company's mission is to provide patients with severe diseases access to new and effective treatment options. With a strong emphasis on research and development, Y-mAbs has built a robust pipeline of promising therapies. Led by a team of experienced professionals, Y-mAbs continues to strive for advancements in healthcare and improved patient outcomes. As a leader in the biopharmaceutical industry, Y-mAbs Therapeutics, Inc remains dedicated to making a positive impact on the lives of patients worldwide.

The main competitors of Y-mAbs Therapeutics, Inc in the market include companies such as Novartis AG, Roche Holding AG, AstraZeneca PLC, Pfizer Inc., and Bristol-Myers Squibb Company.

Y-mAbs Therapeutics, Inc is primarily active in the biotechnology and pharmaceutical industries.

Y-mAbs Therapeutics, Inc. has a specialized business model focused on developing and commercializing innovative antibody-based therapies. As a clinical-stage biopharmaceutical company, Y-mAbs Therapeutics primarily focuses on discovering, developing, and delivering targeted treatments for pediatric cancers. By harnessing the power of antibodies, Y-mAbs Therapeutics aims to address the unmet medical needs of children with cancer and improve their chances of survival and quality of life. Through strategic partnerships, research, and a patient-centered approach, Y-mAbs Therapeutics aims to revolutionize pediatric oncology and make a significant impact in the field of cancer therapeutics.

Y-mAbs Therapeutics에 대한 현재 주가 수익 비율을 계산할 수 없습니다.

Y-mAbs Therapeutics에 대한 현재 KUV는 계산할 수 없습니다.

AlleAktien 품질 점수는 현재 Y-mAbs Therapeutics에 대해 계산할 수 없습니다.

Y-mAbs Therapeutics에 대한 현재 매출은 계산할 수 없습니다.

Y-mAbs Therapeutics의 현재 이익을 계산할 수 없습니다.

Y-mAbs Therapeutics, Inc. is a biopharmaceutical company focused on developing novel cancer drugs specifically targeted to the needs of children and adults with rare, aggressive, and often deadly forms of cancer. The company was founded in 2015 by experienced biotech leaders and has been supported by a variety of private and public financings. Y-mAbs Therapeutics specializes in the development and commercialization of therapeutic antibodies for the treatment of cancer. Their business model focuses on identifying and developing first-in-class or best-in-class therapeutic antibodies that have high efficacy and minimal side effects. The company utilizes advanced technologies and innovative research models to achieve this. Y-mAbs Therapeutics' product pipeline consists of several products in different stages of clinical development. The main antibody in their pipeline is Danyelza (Naxitamab-gqgk), which is used for the treatment of pediatric neuroblastoma. Another antibody in their pipeline is Omburtamab, which is used for the treatment of brain metastases in neuroblastoma patients. In addition to the development of therapeutic antibodies, Y-mAbs Therapeutics also offers diagnostic procedures based on the detection of cancer cell markers. These diagnostic procedures enable early detection of cancer and precise diagnosis of the disease. Y-mAbs Therapeutics' business model strongly focuses on collaboration with other companies and research institutions. The company collaborates with leading clinical facilities and academies to accelerate the development and commercialization of its products. Additionally, the company has entered into several partnerships and licensing agreements with pharmaceutical companies to accelerate the development and commercialization of its products. Y-mAbs Therapeutics aims to expand its global presence. The company plans to market its products in the United States and Europe, seeking approval from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Additionally, the company plans to market its products in Asia and other regions. In summary, Y-mAbs Therapeutics' business model is based on the development and commercialization of novel cancer drugs targeted to the needs of patients with rare and aggressive forms of cancer. The company utilizes advanced technologies and innovative research models to improve the efficacy and safety of its products. Additionally, the company emphasizes collaboration and partnerships with other companies and research institutions to expand its global presence and accelerate the development and commercialization of its products.

Y-mAbs Therapeutics은(는) 연간 번의 배당을 통해 0 USD의 배당금을 지급합니다.

Y-mAbs Therapeutics의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

Y-mAbs Therapeutics의 ISIN은 US9842411095입니다.

Y-mAbs Therapeutics의 WKN은 A2N5R0입니다.

Y-mAbs Therapeutics의 티커는 YMAB입니다.

지난 12개월 동안 Y-mAbs Therapeutics은(는) 의 배당금을 지급했습니다. 이는 약 의 배당 수익률에 해당합니다. 향후 12개월 동안 Y-mAbs Therapeutics은(는) 0 USD의 배당금을 지급할 것으로 예상됩니다.

Y-mAbs Therapeutics의 현재 배당 수익률은 입니다.

Y-mAbs Therapeutics은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

Y-mAbs Therapeutics은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

향후 12개월 동안 0 USD의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

Y-mAbs Therapeutics은 '건강' 섹터에 속합니다.

Y-mAbs Therapeutics의 마지막 배당금을 0 USD만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

마지막 배당금 지급일은 입니다.

2023년에 Y-mAbs Therapeutics는 0 USD를 배당금으로 지급했습니다.

Y-mAbs Therapeutics의 배당금은 USD에 지급됩니다.